Anupam Rasayan India

Catalyst Trusteeship took a pledge over 24,62,215 equity shares of Anupam Rasayan India on 5 October 2026, representing 2.16% of voting capital. The creation took the trustee's encumbered holding to 1,94,29,000 shares, or 17.07% of the company's 11,38,49,841 shares, from 1,69,66,785 shares, or 14.90%. The group funded its Bliss GVS acquisition through a Rs 300 crore term loan and about Rs 1,450 crore of non-controlling, non-voting instruments alongside secured non-convertible debenture structures. Anupam reported consolidated revenue of about Rs 2,384 crore for FY26, with pro forma revenue of more than Rs 4,000 crore across Anupam, Tanfac, Jayhawk and Bliss. Bliss added six manufacturing facilities and more than 150 brands at about 30% capacity utilisation, while the legacy business operated eight facilities with installed capacity of more than 2,00,000 tonnes.

Powered by Tijori

Anupam Rasayan promoter Mona Anandbhai Desai created fresh pledges over 40,40,625 shares in favour of Catalyst Trusteeship and released pledges over 26,80,000 shares held with STCI Finance and Aditya Birla Capital in late September. The two creations comprised 14,60,625 shares on 23 September and 25,80,000 shares on 30 September as security for Rs 300 crore of debentures issued by Mates Visa Consultancy and Rs 278 crore issued by Rehash Industrial. The releases covered 7,00,000 shares from STCI Finance and 19,80,000 shares from Aditya Birla Capital on 29 September after repayment, leaving 40,40,625 shares, or 97.58% of her holding, encumbered. Mates Visa was the wholly owned vehicle used to consummate the acquisition of a 50.07% controlling stake in Bliss GVS Pharma that closed on 28 September. The four-business group carried pro forma revenue of more than Rs 4,000 crore, with Bliss contributing Rs 927 crore alongside standalone revenue of Rs 1,676 crore, Tanfac at Rs 711 crore and Jayhawk at Rs 722 crore. Anupam reported consolidated revenue of about Rs 2,384 crore for FY26.

Powered by Tijori

An additional 66.05 lakh Anupam Rasayan India shares, representing 5.80% of the equity, were pledged in favour of Catalyst Trusteeship on 30 September 2026. Total shares encumbered in favour of Catalyst rose to 169.66 lakh shares, or 14.90% of the equity, from 103.61 lakh shares, or 9.10%, created on 23 and 25 September. Anupam Rasayan reported consolidated revenue of about ₹2,384 crore for FY26, with pro forma revenue above ₹4,000 crore across four businesses including Bliss GVS Pharma. The company served more than 200 domestic and international customers in custom synthesis and speciality chemicals, with exports at 58% of revenue in the first half of FY26.

Powered by Tijori

Anand Sureshbhai Desai pledged 31.4 lakh Anupam Rasayan India shares on 22 September and a further 39.01 lakh shares on 23 September, while Shraddha Anand Desai pledged 50 lakh shares on 23 September. The 31.4 lakh-share pledge secured ₹145 crore of non-convertible debentures issued by Anupam Rasayan to Aditya Birla Capital, the 39.01 lakh-share pledge secured debentures issued by Mates Visa Consultancy and Rehash Industrial and Resins Chemicals, and the 50 lakh-share pledge secured a loan taken by Anand Desai from Tata Capital. Anand Desai held 1,10,76,940 shares with 1,08,76,940 shares encumbered after the creations, while Shraddha Desai held 77,86,435 shares with 50 lakh shares encumbered. The pledges came after the company allotted ₹145 crore of 10.25% secured debentures to Aditya Birla Capital on 21 September and after 33.4 lakh Anand Desai shares were released on 21 September on partial redemption of a ₹160 crore debenture tranche. Anupam Rasayan reported consolidated revenue of about ₹2,384 crore for FY26, with four-business pro forma revenue of more than ₹4,000 crore and EBITDA of about ₹834 crore spanning Anupam standalone, Tanfac, Jayhawk and Bliss GVS Pharma. Bliss GVS Pharma, in which Anupam took 50.07% control with persons acting in concert on 28 September, operated six manufacturing facilities at about 30% utilisation and filed turnover of ₹798.98 crore for FY26.

Powered by Tijori

Catalyst Trusteeship disclosed creation of a pledge over 10,361,785 equity shares representing 9.10% of Anupam Rasayan India's equity capital, acting as debenture trustee for debenture holders. The pledge was created in two tranches, with 5,361,785 shares on 23 September 2026 and 5,000,000 shares on 25 September 2026. A Rs 160 crore non-convertible debenture tranche allotted in May 2026 to Aditya Birla Capital was secured by 31.5 lakh promoter shares. The company closed acquisition of 50.07% control in Bliss GVS Pharma with persons acting in concert on 28 September 2026 and reported consolidated revenue of about Rs 2,384 crore for FY26, with pro forma revenue of more than Rs 4,000 crore across four businesses. Bliss operated six facilities at about 30% utilisation and filed turnover of Rs 798.98 crore for FY26.

Powered by Tijori

Anupam Rasayan India paid consideration for a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share through its wholly owned subsidiary Mates Visa Consultancy, completing the transaction signed on 23 May 2026 after the mandatory open offer. The deal was funded with a ₹300 crore term loan and about ₹1,450 crore of non-controlling, non-voting instruments from investors led by Bain Capital alongside Trust Group and Investec. The combined group of Anupam Rasayan, Tanfac Industries, Jayhawk Fine Chemicals and Bliss GVS was presented with pro-forma revenue of more than ₹4,000 crore and EBITDA of about ₹834 crore. Bliss GVS operated six formulation facilities across Maharashtra certified to US FDA, EU-GMP and WHO-GMP standards with a portfolio of more than 150 brands and utilisation of about 30%. The open offer for a 26% stake at ₹299 per share was managed through SBI Capital Markets. Anupam Rasayan reported consolidated revenue of ₹2,383.6 crore in FY26 with net debt of ₹730 crore after warrant proceeds, and its order book of letters of intent and contracts stood at about ₹18,000 crore in August 2026.

Powered by Tijori

Aug 14 (Reuters) - Anupam Rasayan India Ltd ANUY.NS:

• ANUPAM RASAYAN INDIA LTD - NAMES RAVI DESAI AS CHIEF OPERATING OFFICER

Source text: ID:nBSE3tzdhx

Further company coverage: ANUY.NS

(([email protected];))

Anupam Rasayan India Ltd signed a non-binding Letter of Intent with BASQUEVOLT, S.A., a Spanish developer of solid-state lithium batteries, to explore the potential long-term supply of a specialty chemical product. The LOI envisages cumulative revenue of up to $300 million over 10 years, though any supply remains subject to successful product development and a definitive commercial agreement. The move marks Anupam Rasayan's deepening foray into the electronic chemicals domain, a sector the company has identified as a key growth driver. Managing Director Anand Desai said the LOI reinforces the company's strategic focus and leverages its R&D strengths to cater to advanced manufacturing and technology-driven industries.

Powered by Tijori

July 15 (Reuters) - Anupam Rasayan India Ltd ANUY.NS:

• ANUPAM RASAYAN INDIA - SIGNS LOI WITH BASQUEVOLT FOR POTENTIAL SUPPLY WORTH $300 MILLION

• ANUPAM RASAYAN INDIA - LOI COVERS POTENTIAL SUPPLY OVER UP TO 10 YEARS FOR $300 MILLION

Source text: ID:nBSE2m6DTy

Further company coverage: ANUY.NS

(([email protected];))

** Bliss GVS Pharma BLIS.NS stock rises more than 2% to 307.35 rupees, Anupam Rasayan India ANUY.NS down 1.5%

** Specialty chem firm ANUY to buy up to 74.2% Bliss stake, according to filing

** 45.8 mln shares, equivalent to 43.3% stake, for up to 13.7 bln rupees ($143.7 mln) from promoters and investors, 26% stake from public shareholders worth 8.29 bln rupees

** ANUY also has an option to acquire another 4.9% residual stake from sellers

** YTD, BLIS up about 88% and ANUY up around 2%

($1 = 95.3675 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

Feb 13 (Reuters) - Anupam Rasayan India Ltd ANUY.NS:

• DENIES PLANS TO BUY STAKE IN BLISS GVS PHARMA

Source text: ID:nBSE3BlFP7

Further company coverage: ANUY.NS

(([email protected];))

March 10 (Reuters) - Anupam Rasayan India Ltd ANUY.NS:

• ANUPAM RASAYAN INDIA LTD - SIGNS $106 MILLION LOI WITH KOREAN MNC

• ANUPAM RASAYAN INDIA LTD - SIGNS 10-YEAR LOI WITH A KOREAN MNC

Source text: ID:nBSE88jRV1

Further company coverage: ANUY.NS

(([email protected];))

** Shares of Anupam Rasayan India ANUY.NS rise as much as 2.5% to 643.8 rupees, now up 1.4%

** The specialty chemicals maker said on Friday it signed a contract with U.S.-based Elementium Materials for development and supply of advanced solvent for EV battery chemicals

** Co expects cumulative sales ranging between $350 mln to $450 mln

** Supply expected to commence from end of FY26; agreement to be negotiated for 5 years

** 8 analysts covering the stock on avg have a "buy" rating; median PT is 685 rupees - data compiled by LSEG

** Stock snaps four-day losing streak

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of Anupam Rasayan India ANUY.NS rise 2.6% to 686 rupees, in their busiest session in over six months

** Specialty chemicals maker's Q3 consol profit surges 53% Y/Y, helped by strong demand in pharma and polymer segments; rev up 32%

** Co aims for 30%-35% increase in rev in FY26

** Co also signs a $12.5 mln per annum contract with a US co for supply of a specialty chemical product

** More than 750,000 shares traded, over nine times their 30-day avg

** Avg of rating by analysts covering the stock is "hold," same as that on peer Deepak Nitrite DPNT.NS - LSEG

** Their median PT is 737.5 rupees - LSEG

** Stock declined 31% in 2024 vs flat DPNT shares

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Feb 13 (Reuters) - Anupam Rasayan India Ltd ANUY.NS:

• ANUPAM RASAYAN INDIA DEC-QUARTER CONSOL NET PROFIT 281.9 MILLION RUPEES

• ANUPAM RASAYAN INDIA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.9 BILLION RUPEES

Source text: ID:nBSEbTgMMl

Further company coverage: ANUY.NS

(([email protected];))

** Shares of Anupam Rasayan India ANUY.NS fall 2.3% to 718.35 rupees

** The specialty chemicals co's Q2 consol net profit fall 59% y/y, revenue down 25% y/y

** Trading vols 1.2x 30-day average

** Stock down ~32% YTD

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Anupam Rasayan India ANUY.BO up 3.7%

** Stock rose as much as 6.9% in early trade to 945.05 rupees

** The industrial chemicals manufacturer on Tuesday signed a letter of intent worth about $90 million with a Japanese multinational company to supply two advanced intermediates using fluorination chemistry

** Stock on track for a fourth consecutive session of gains, if trend holds

** More than 13,000 shares change hands in early trade, 1.7x its 30-day avg

** Average rating of nine analysts covering ANUY is "hold", their median PT is 812 rupees - LSEG data

** Including session's move, stock is down 12.6% YTD

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

April 2 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• SIGNS LOI WITH JAPANESE MULTINATIONAL WORTH ABOUT $90 MILLION

Source text for Eikon: ID:nBSEc8bQWJ

Further company coverage: ANUY.BO

(([email protected];))

Feb 12 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• ANUPAM RASAYAN INDIA DEC-QUARTER CONSOL NET PROFIT 184.1 MILLION RUPEES VERSUS 429.1 MILLION RUPEES

• ANUPAM RASAYAN INDIA LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 2.96 BILLION RUPEES VERSUS 3.92 BILLION RUPEES

• ANUPAM RASAYAN INDIA - TO SET-UP HYBRID POWER PLANT OF A TOTAL CAPACITY OF 9.6 MW IN BHARUCH

Source text for Eikon: ID:nNSE2MG0BN

Further company coverage: ANUY.BO

(([email protected];))

Dec 25 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• SIGNS LETTER OF INTENT WORTH $61 MILLION

• SIGNS LETTER OF INTENT WITH A JAPANESE MULTI NATIONAL CHEMICAL CO

Source text for Eikon: ID:nNSE7NT7XD

Further company coverage: ANUY.BO

(([email protected];))

** Indian speciality chemical cos' price realisations getting hurt in refrigerant gas segment in U.S. due to China's dumping and lower prices, says Emkay Global

** Cos will shift more towards Gulf/domestic markets from U.S. for their new capacity additions and compete with Chinese imports, reducing price benefit for cos - Emkay

** Emkay says US seeing higher imports from United Arab Emirates from new huge capacity addition by a JV between IGas Holdings (IGas) in US and China's Juhua Group

** Brokerage says Indian cos will have to strategize on optimizing between volumes and price and turn cautious on refrigerant gas business

** Emkay maintains "buy" on SRF SRFL.NS and Anupam Rasyan ANUY.BO, "hold" on Navin Flourine NAFL.NS and "sell" on Gujarat Fluorochemicals GUJL.NS

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Nov 7 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• SEPT-QUARTER CONSOL NET PROFIT 406.9 MILLION RUPEES VERSUS PROFIT 415.7 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.92 BILLION RUPEES VERSUS 3.93 BILLION RUPEES

Source text for Eikon: ID:nNSE386ddL

Further company coverage: ANUY.BO

(([email protected];))

Nov 2 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• TO CONSIDER PROPOSAL FOR RAISING OF FUNDS

Source text for Eikon: ID:nBSE8SdhCd

Further company coverage: ANUY.BO

(([email protected];))

Sept 7 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• NAMES GOPAL AGRAWAL AS CEO

Source text for Eikon: ID:nBSE2Rb452

Further company coverage: ANUY.BO

(([email protected];;))

Aug 1 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• APPROVED PURCHASE OF 100% SHAREHOLDING OF ARIL FLUOROSPECIALITY

Source text for Eikon: ID:nNSE31rvL1

Further company coverage: ANUY.BO

(([email protected];))

July 3 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• ANUPAM RASAYAN INDIA LTD - ANUPAM RASAYAN SIGNS MEMORANDUM OF UNDERSTANDING WITH 3XPER INNOVENTURE LIMITED

• ANUPAM RASAYAN INDIA LTD - MOU FOR SUPPLY OF TARGETED AND IDENTIFIED NEW AGE PHARMA MOLECULES

Source text for Eikon: ID:nNSE1mKMFv

Further company coverage: ANUY.BO

(([email protected];))

** Shares of Anupam Rasayan India ANUY.NS rise as much as 5.9% to 1,150 rupees, biggest intraday pct gain since May 31

** The industrial chemicals manufacturer on Tuesday signed a Letter of Intent (LOI) worth $265 million with a Japanese speciality chemical company

** Stock hits highest level since June 1

** About 503,125 shares change hands by 9:31 a.m. IST, vs 30-day avg of 336,735 shares - Refinitiv Data

** Two out of 7 analysts covering the stock have a "buy" or higher rating, while one has "hold" and four rate it as "sell" or "strong sell"; median PT is 1,020 rupees

** Stock up ~60% YTD as of last close

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

June 13 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• SIGNS LETTER OF INTENT WORTH $265 MILLION WITH JAPANESE SPECIALITY CHEMICAL CO

Source text for Eikon: ID:nBSE8y92tr

Further company coverage: ANUY.BO

(([email protected];;))

May 9 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• LONG TERM CONTRACT WORTH $53 MILLION RENEWED WITH GERMAN MULTINATIONAL

• CONTRACT FOR SUPPLY OF PATENTED LIFE SCIENCE SPECIALITY CHEMICAL FOR NEXT 3 YEARS ON EXCLUSIVE BASIS

Source text for Eikon: ID:nBSETxvBr

Further company coverage: ANUY.BO

(([email protected];))

May 3 (Reuters) - Anupam Rasayan India Ltd ANUY.BO:

• MARCH-QUARTER CONSOL NET PROFIT 566.8 MILLION RUPEES VERSUS 461 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 4.8 BILLION RUPEES VERSUS 3.25 BILLION RUPEES

• DIVIDEND 1.5 RUPEES PER SHARE

Source text for Eikon: ID:nBSE9dzTw6

Further company coverage: ANUY.BO

(([email protected];))